Todos os posts

M-A de estudos randomizados | Uso de torniquete na artroplastia total de joelho e risco de infecção.

5 Jul, 2022 | 11:23h

Tourniquet use in total knee arthroplasty and the risk of infection: a meta-analysis of randomised controlled trials – Journal of Experimental Orthopaedics

---

Estudo de coorte | Novos modelos de predição de risco para determinar desfechos adversos de insuficiência cardíaca na cardiomiopatia ventricular direita arritmogênica.

5 Jul, 2022 | 11:22h

Novel Risk Prediction Model to Determine Adverse Heart Failure Outcomes in Arrhythmogenic Right Ventricular Cardiomyopathy – Journal of the American Heart Association

Editorial: Predicting Heart Failure in Arrhythmogenic Right Ventricular Cardiomyopathy

---

FDA alerta sobre possível risco aumentado de morte e de sérios efeitos adversos com uso de duvelisibe.

5 Jul, 2022 | 11:21h

FDA Warns About Possible Increased Risk of Death and Serious Side Effects With Duvelisib – The ASCO Post

---

Editorial | Impacto das células tumorais circulantes como componentes do estadiamento do mieloma múltiplo.

5 Jul, 2022 | 11:19h

Circulating Tumor Cell Burden as a Component of Staging in Multiple Myeloma: Ready for Prime Time? – Journal of Clinical Oncology

Estudos originais:

Circulating Tumor Cells for the Staging of Patients With Newly Diagnosed Transplant-Eligible Multiple Myeloma – Journal of Clinical Oncology

High Levels of Circulating Tumor Plasma Cells as a Key Hallmark of Aggressive Disease in Transplant-Eligible Patients With Newly Diagnosed Multiple Myeloma – Journal of Clinical Oncology

Identification of High-Risk Multiple Myeloma With a Plasma Cell Leukemia-Like Transcriptomic Profile – Journal of Clinical Oncology

---

Diretrizes 2022 para o tratamento e a profilaxia do tromboembolismo venoso em pacientes com câncer, incluindo aqueles com COVID-19.

4 Jul, 2022 | 12:24h

2022 international clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer, including patients with COVID-19 – The Lancet Oncology

Conteúdos relacionados:

Primary prophylaxis for venous thromboembolism in ambulatory cancer patients receiving chemotherapy – Cochrane Library

American Society of Hematology 2021 guidelines for management of venous thromboembolism: prevention and treatment in patients with cancer – Blood Advances

Cancer-Associated Venous Thromboembolic Disease, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology – Journal of the National Comprehensive Cancer Network

Venous and Arterial Thromboembolism in Patients With Cancer: JACC: CardioOncology State-of-the-Art Review

---

Dois novos estudos mostram que a enoxaparina não tem benefício na tromboprofilaxia primária de pacientes ambulatoriais sintomáticos com COVID-19.

4 Jul, 2022 | 12:23h

Estudo 1: Enoxaparin for primary thromboprophylaxis in symptomatic outpatients with COVID-19 (OVID): a randomised, open-label, parallel-group, multicentre, phase 3 trial – The Lancet Haematology

Estudo 2: Thromboprophylactic low-molecular-weight heparin versus standard of care in unvaccinated, at-risk outpatients with COVID-19 (ETHIC): an open-label, multicentre, randomised, controlled, phase 3b trial – The Lancet Haematology

Comentários:

Antithrombotic prophylaxis for symptomatic outpatients with COVID-19: less is consistently more – The Lancet Haematology

Antithrombotic Prophylaxis No Help in Outpatients With COVID — Two trials show no differences between patients who received enoxaparin vs standard of care – MedPage Today (necessário cadastro gratuito)

 

Comentário no Twitter (fio – clique para saber mais)

Early in the pandemic we wondered whether antithrombotic therapy in outpatients with #COVID19 would prevent #thrombosis ❓

Several trials were started globally and the ACTIV-4B trial was previously reported⬇️ https://t.co/Q15WcZwDIA

Now, we publish the OVID and ETHIC trials🧵

— The Lancet Haematology (@TheLancetHaem) June 30, 2022

 

---

Estudo randomizado | Uma dose única e imediata de tenecteplase é não inferior à alteplase para tratar pacientes com AVC isquêmico agudo.

4 Jul, 2022 | 12:21h

Intravenous tenecteplase compared with alteplase for acute ischaemic stroke in Canada (AcT): a pragmatic, multicentre, open-label, registry-linked, randomised, controlled, non-inferiority trial – The Lancet (link para o resumo – $ para o texto completo)

Comunicado de imprensa: UCalgary researchers with the Calgary Stroke Program make another breakthrough in the treatment of stroke

---

Revisão sistemática | Treinamento para aumentar a mobilidade e a função em idosos frágeis.

4 Jul, 2022 | 12:19h

Mobility training for increasing mobility and functioning in older people with frailty – Cochrane Library

Resumo: Mobility training for increasing mobility and functioning in older people who are frail – Cochrane Library

---

Acurácia do teste rápido de antígeno vs. RT-PCR para infecção por SARS-CoV-2 em atletas universitários durante a prevalência da variante Ômicron.

4 Jul, 2022 | 12:18h

Accuracy of Rapid Antigen vs Reverse Transcriptase–Polymerase Chain Reaction Testing for SARS-CoV-2 Infection in College Athletes During Prevalence of the Omicron Variant – JAMA Network Open

 

Comentário no Twitter

In this case series of college athletes returning to campus during Omicron, rapid antigen tests were 63% sensitive, >99% specific for #COVID19, similar to previous strains and less well in detecting asymptomatic #SARSCoV2. @helixcardinal @stanford_ortho https://t.co/SBPr6NQ9Na

— JAMA Network Open (@JAMANetworkOpen) June 15, 2022

 

---

Estudo de coorte | Efetividade das vacinas Pfizer, Moderna e AstraZeneca contra desfechos graves de Covid-19 em um cenário de vacinação em massa de abrangência nacional.

4 Jul, 2022 | 12:16h

Effectiveness of BNT162b2, mRNA-1273, and ChAdOx1-S vaccines against severe covid-19 outcomes in a nationwide mass vaccination setting: cohort study – BMJ Medicine

 

Comentário no Twitter

🎉 Read our latest research article comparing the effectiveness of three #COVID vaccines against severe COVID outcomes. ▶️ https://t.co/uaQNgnDrrV#BMJMedicine #MedTwitter #openaccess pic.twitter.com/4oeG5d0j80

— BMJMedicine (@BMJMedicine) June 16, 2022

 

---